{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:13:47Z","timestamp":1789035227978,"version":"build-2803163510"},"reference-count":122,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Metabolic syndrome came to the attention of the scientific community several decades ago, and its definition has undergone multiple changes over time. It is currently defined by the coexistence of hypertension, central obesity, dyslipidemia, and impaired glucose metabolism, with insulin resistance, chronic inflammation, and oxidative stress representing important underlying pathophysiological mechanisms. The latter two processes are major promoters of the onset and progression of atherosclerosis. In parallel, many individuals develop metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (NAFLD). Growing evidence indicates that MASLD may interact bidirectionally with cardiovascular, renal, and metabolic dysfunction and may contribute to cardiometabolic risk. These observations have prompted proposals for a broader cardio\u2013reno\u2013hepato\u2013metabolic axis. However, MASLD is not currently included in the established cardiovascular-kidney-metabolic (CKM) definition or staging system, and its incorporation remains an evolving conceptual extension. Prediabetes is a reversible condition characterized by abnormal glucose levels that do not meet the diagnostic criteria for diabetes. The American Diabetes Association defines prediabetes as glycated hemoglobin (HbA1c) = 5.7\u20136.4%, fasting plasma glucose = 100\u2013125 mg\/dL, or two-hour plasma glucose during an oral glucose tolerance test = 140\u2013199 mg\/dL. This comprehensive review examines traditional and genetic risk determinants, shared pathophysiological mechanisms, diagnostic strategies, clinical manifestations, emerging phenotypes, circulating microRNAs as non-invasive biomarkers, complications, and the principal therapeutic strategies, including diet, exercise, and pharmacotherapy. Particular attention is given to the recent approvals of resmetirom and semaglutide for metabolic dysfunction-associated steatohepatitis and to the expanding roles of sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and non-steroidal mineralocorticoid receptor antagonists. Cardiovascular, renal, metabolic, and hepatic disorders are frequently present in the same patient. Other individuals may develop this high-risk cluster over time. The aim of this article is to define the interplay between different metabolic conditions and to outline the best approach to diagnosis, monitoring, and effective integrated therapy.<\/jats:p>","DOI":"10.3390\/medicina62091742","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:13:03Z","timestamp":1789031583000},"page":"1742","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular\u2013Kidney\u2013Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review"],"prefix":"10.3390","volume":"62","author":[{"given":"Vasilica","family":"Enache","sequence":"first","affiliation":[{"name":"Department of Cardiology, Clinical Emergency Hospital Sf\u00e2ntul Pantelimon, 021659 Bucharest, Romania"},{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Cristian","family":"Popescu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Emergency Hospital Sf\u00e2ntul Pantelimon, 021659 Bucharest, Romania"},{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Faculty of Medicine, Transilvania University, 500036 Brasov, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Marcu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Emergency Hospital Sf\u00e2ntul Pantelimon, 021659 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5167-6738","authenticated-orcid":false,"given":"Mara","family":"Diaconu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Emergency Hospital Sf\u00e2ntul Pantelimon, 021659 Bucharest, Romania"},{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Faculty of Medicine, Transilvania University, 500036 Brasov, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru-Cristian","family":"Nechita","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Emergency Hospital Sf\u00e2ntul Pantelimon, 021659 Bucharest, Romania"},{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"ref_1","unstructured":"Writing Committee Members, Ndumele, C.E., Rodriguez, F., Dixon, D.L., Khan, S.S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., and Breathett, K. (2026). 2026 AHA\/ACC\/ADA\/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 154, e50\u2013e158."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1681\/ASN.0000000000000323","article-title":"Cardiovascular-Kidney-Metabolic Health Syndrome: What Does the American Heart Association Framework Mean for Nephrology?","volume":"35","author":"Bansal","year":"2024","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"(2001). Expert Panel on Detection Evaluation Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 285, 2486\u20132497.","DOI":"10.1001\/jama.285.19.2486"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: An American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome\u2014A new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"key":"ref_6","unstructured":"International Diabetes Federation (2006). The IDF Consensus Worldwide Definition of the Metabolic Syndrome, IDF."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet. Med."},{"key":"ref_8","unstructured":"World Health Organization (1999). Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part 1, Diagnosis and Classification of Diabetes Mellitus, World Health Organization. Available online: https:\/\/iris.who.int\/handle\/10665\/66040."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1046\/j.1464-5491.1999.00059.x","article-title":"Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)","volume":"16","author":"Balkau","year":"1999","journal-title":"Diabet. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_12","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol., 81, 492\u2013542."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1515\/jtim-2025-0049","article-title":"Cardiovascular-kidney-metabolic: Hype or a focus on front-line health?","volume":"13","author":"Cai","year":"2025","journal-title":"J. Transl. Int. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"sfaf260","DOI":"10.1093\/ckj\/sfaf260","article-title":"The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: Interconnections and management","volume":"18","author":"Moncho","year":"2025","journal-title":"Clin. Kidney J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.2024.6892","article-title":"Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011\u20132020","volume":"331","author":"Aggarwal","year":"2024","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101407","DOI":"10.1016\/j.ajpc.2026.101407","article-title":"Associations between cardiovascular-kidney-metabolic syndrome staging and risks of all-cause and cardiovascular mortality: A systematic review and meta-analysis","volume":"25","author":"Ding","year":"2026","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s11739-025-03895-6","article-title":"Global burden and risk factors of MASLD: Trends from 1990 to 2021 and predictions to 2030","volume":"20","author":"Huang","year":"2025","journal-title":"Intern. Emerg. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101898","DOI":"10.1016\/j.aohep.2025.101898","article-title":"Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990\u20132021 to 2045","volume":"30","author":"Kan","year":"2025","journal-title":"Ann. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"GBD 2023 MASLD Collaborators (2026). Global burden of metabolic dysfunction-associated steatotic liver disease, 1990\u20132023, and projections to 2050: A systematic analysis for the Global Burden of Disease Study 2023. Lancet Gastroenterol. Hepatol., 11, 463\u2013494.","DOI":"10.2139\/ssrn.6677198"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Surma, S., and Bu\u0142dak, \u0141. (2025). Editorial: Metabolic dysfunction-associated steatotic liver disease (MASLD)\u2014Pathogenesis, prevention and treatment. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1703019"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mustafa, A., Kite, C., Lagojda, L., Dallaway, A., Chatha, K.K., Than, N.N., Kassi, E., Kyrou, I., and Randeva, H.S. (2025). Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262311275"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Olaez-Ramos, C.E., Mojica-Zamudio, K.L., Sandoval-Rodr\u00edguez, A., and Armend\u00e1riz-Borunda, J. (2026). Epidemiology and diagnostic of MASLD in Latin America: A yet to be met challenge. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1700072"},{"key":"ref_25","first-page":"559331","article-title":"Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH)","volume":"20","author":"Michel","year":"2026","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2516381","DOI":"10.1001\/jamanetworkopen.2025.16381","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease-The New Epidemic of Chronic Liver Disease","volume":"8","author":"Kamath","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"109815","DOI":"10.1016\/j.isci.2024.109815","article-title":"Unsupervised clustering identified clinically relevant metabolic syndrome endotypes in UK and Taiwan Biobanks","volume":"27","author":"Lim","year":"2024","journal-title":"iScience"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e186424","DOI":"10.1172\/JCI186424","article-title":"Human genetics of metabolic dysfunction-associated steatotic liver disease: From variants to cause to precision treatment","volume":"135","author":"Chen","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yao, H., Xia, Z., Liu, Y., Dong, M., Yang, K., and Zhou, F. (2025). PNPLA3-Ile148Met and TM6SF2-Glu167Lys increase susceptibility to metabolic dysfunction-associated steatotic liver disease in children. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1689656"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e16103","DOI":"10.1111\/liv.16103","article-title":"Integrating PNPLA3 into clinical risk prediction","volume":"45","author":"Chen","year":"2025","journal-title":"Liver Int."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Moonlisarn, K., Somnark, P., Boonkaew, B., Bunchorntavakul, C., and Tangkijvanich, P. (2024). Interaction Between PNPLA3 and SIRT5 Genetic Variants in Association with Liver Fibrosis Severity in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. Genes, 15.","DOI":"10.3390\/genes15111370"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s40246-025-00834-6","article-title":"Genetic polymorphisms associated with metabolic dysfunction-associated steatotic liver disease and cardiometabolic risk susceptibility in the Chinese Han population","volume":"19","author":"Dai","year":"2025","journal-title":"Hum. Genom."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101649","DOI":"10.1016\/j.jhepr.2025.101649","article-title":"PNPLA3 and TM6SF2 exacerbate the impact of alcohol and metabolic dysfunction on liver fibrosis","volume":"8","author":"Gensluckner","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","article-title":"Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Jamialahmadi","year":"2024","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102170","DOI":"10.1016\/j.aohep.2025.102170","article-title":"Genetic risk factors for MASLD\/MASH and cardiovascular disease in elderly individuals","volume":"31","author":"Theel","year":"2026","journal-title":"Ann. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","article-title":"Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms","volume":"83","author":"Steinberg","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kolb, H. (2022). Obese visceral fat tissue inflammation: From protective to detrimental?. BMC Med., 20.","DOI":"10.1186\/s12916-022-02672-y"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zatterale, F., Longo, M., Naderi, J., Raciti, G.A., Desiderio, A., Miele, C., and Beguinot, F. (2020). Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol., 10.","DOI":"10.3389\/fphys.2019.01607"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.3390\/ijms15046184","article-title":"Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease","volume":"15","author":"Jung","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/ijpvm.IJPVM_193_20","article-title":"Adiponectin: Role in Physiology and Pathophysiology","volume":"11","author":"Nguyen","year":"2020","journal-title":"Int. J. Prev. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cca.2007.01.026","article-title":"Adiponectin as an anti-inflammatory factor","volume":"380","author":"Ouchi","year":"2007","journal-title":"Clin. Chim. Acta."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., and Singh, B.K. (2024). Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1433857"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ito, F., and Ito, T. (2020). High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease. Antioxidants, 9.","DOI":"10.3390\/antiox9050362"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e70137","DOI":"10.1111\/1753-0407.70137","article-title":"Association Between Serum Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A 3-Year Longitudinal Cohort Study (2019\u20132022)","volume":"17","author":"Zhao","year":"2025","journal-title":"J. Diabetes"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"III27","DOI":"10.1161\/01.CIR.0000131515.03336.f8","article-title":"Role of endothelial dysfunction in atherosclerosis","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2478\/jtim-2022-0012","article-title":"Inflammatory Factors Driving Atherosclerotic Plaque Progression New Insights","volume":"10","author":"Song","year":"2022","journal-title":"J. Transl. Int. Med."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Sun, H.J., Wu, Z.Y., Nie, X.W., and Bian, J.S. (2020). Role of Endothelial Dysfunction in Cardiovascular Diseases: The Link Between Inflammation and Hydrogen Sulfide. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.01568"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Batty, M., Bennett, M.R., and Yu, E. (2022). The Role of Oxidative Stress in Atherosclerosis. Cells, 11.","DOI":"10.3390\/cells11233843"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Henein, M.Y., Vancheri, S., Longo, G., and Vancheri, F. (2022). The Role of Inflammation in Cardiovascular Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112906"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jacc.2025.12.015","article-title":"MASLD, MASH, and the CKM Spectrum: A Roadmap for Multiorgan Clinical Trial Design","volume":"87","author":"Zannad","year":"2026","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Bogdan, R.G., Boicean, A., Anderco, P., Ichim, C., Iliescu-Glaja, M., Todor, S.B., Leonte, E., Bloanca, V.A., Crainiceanu, Z.P., and Popa, M.L. (2025). From Liver to Kidney: The Overlooked Burden of Nonalcoholic Fatty Liver Disease in Chronic Kidney Disease. J. Clin. Med., 14.","DOI":"10.3390\/jcm14072486"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Mitroi Sakizlian, D.D., Boldeanu, L., Mitrea, A., Clenciu, D., Vladu, I.M., Ciobanu Plasiciuc, A.E., \u0218arla, A.V., Silo\u0219i, I., Boldeanu, M.V., and Assani, M.Z. (2025). The Interplay of Cardiometabolic Syndrome Phenotypes and Cardiovascular Risk Indices in Patients Diagnosed with Diabetes Mellitus. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26136227"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.gastro.2026.01.047","article-title":"Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"171","author":"Kanwal","year":"2026","journal-title":"Gastroenterology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values","volume":"59","author":"Lichtinghagen","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2021). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J. Hepatol., 75, 659\u2013689.","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cmet.2017.07.008","article-title":"Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans","volume":"26","author":"Stefan","year":"2017","journal-title":"Cell Metab."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Kim, J. (2025). Metabotype Risk Clustering Based on Metabolic Disease Biomarkers and Its Association with Metabolic Syndrome in Korean Adults: Findings from the 2016\u20132023 Korea National Health and Nutrition Examination Survey (KNHANES). Diseases, 13.","DOI":"10.3390\/diseases13080239"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"180","DOI":"10.14744\/hf.2025.17142","article-title":"Role of micrornas in the pathophysiology and diagnosis of metabolic dysfunction-associated steatotic liver disease: A bibliometric review","volume":"6","author":"Locatelli","year":"2025","journal-title":"Hepatol. Forum."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Jiang, L., Li, L., Zhang, K., Zheng, L., Zhang, X., Hou, Y., Cao, M., and Wang, Y. (2025). A systematic review and meta-analysis of microRNAs in the diagnosis of early diabetic kidney disease. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1432652"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Iside, C., Picone, F., Di Pietro, P., Abate, A.C., Prete, V., Damato, A., Venturini, E., Akeel, S., Petralia, S., and Vecchione, C. (2025). MicroRNA Signatures in Cardiometabolic Disorders as a Next-Generation Diagnostic Approach: Current Insight. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262110769"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Bia\u0142ek, D., Wunsch, E., Kempi\u0144ska-Podhorodecka, A., Abramczyk, J., Wunsch, A., and Koz\u0142owska, K. (2025). MicroRNA and Protein Biomarkers of Intestinal Permeability in the Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262311351"},{"key":"ref_66","first-page":"1438","article-title":"Extracellular vesicles and microRNAs in metabolic dysfunction-associated steatotic liver disease: From steatosis to hepatocellular carcinoma","volume":"24","author":"Keingeski","year":"2025","journal-title":"EXCLI J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis","volume":"56","author":"Mottillo","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Sedaghat, Z., Khodakarim, S., Nejadghaderi, S.A., and Sabour, S. (2024). Association between metabolic syndrome and myocardial infarction among patients with excess body weight: A systematic review and meta-analysis. BMC Public Health, 24.","DOI":"10.1186\/s12889-024-17707-7"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cvr\/cvaa217","article-title":"Metabolic inflammation in heart failure with preserved ejection fraction","volume":"117","author":"Schiattarella","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Xie, Z., Li, J., Chen, C., Cai, W., Dong, Y., Xue, R., and Liu, C. (2021). Meta-analysis of metabolic syndrome and its individual components with risk of atrial fibrillation in different populations. BMC Cardiovasc. Disord., 21.","DOI":"10.1186\/s12872-021-01858-1"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.numecd.2008.04.001","article-title":"Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: The Strong Heart Study","volume":"19","author":"Devereux","year":"2009","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijcard.2023.03.024","article-title":"Metabolic syndrome and risk of incident heart failure in non-diabetic patients with established cardiovascular disease","volume":"379","author":"Burger","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Michelotti, A., de Scordilli, M., Palmero, L., Guardascione, M., Masala, M., Roncato, R., Foltran, L., Ongaro, E., and Puglisi, F. (2021). NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. Cells, 10.","DOI":"10.3390\/cells10082034"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"101193","DOI":"10.1016\/j.jhepr.2024.101193","article-title":"Differential prevalence and prognostic value of metabolic syndrome components among patients with MASLD","volume":"6","author":"Pustjens","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e13649","DOI":"10.1111\/obr.13649","article-title":"Association of metabolic syndrome and chronic kidney disease","volume":"25","author":"Scurt","year":"2024","journal-title":"Obes. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s-Camacho, F., Zambrano-V\u00e1squez, O.R., Ar\u00e9chaga-Ocampo, E., Casta\u00f1eda-S\u00e1nchez, J.I., Gonzaga-S\u00e1nchez, J.G., S\u00e1nchez-Gloria, J.L., S\u00e1nchez-Lozada, L.G., and Osorio-Alonso, H. (2024). Sodium-Glucose Cotransporter Inhibitors: Cellular Mechanisms Involved in the Lipid Metabolism and the Treatment of Chronic Kidney Disease Associated with Metabolic Syndrome. Antioxidants, 13.","DOI":"10.3390\/antiox13070768"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/joim.13355","article-title":"Association of the metabolic syndrome with mortality and major adverse cardiac events: A large chronic kidney disease cohort","volume":"290","author":"Pammer","year":"2021","journal-title":"J. Intern. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/CIRCOUTCOMES.112.966903","article-title":"Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: A systematic review and meta-analysis of cohort studies","volume":"6","author":"Vlachopoulos","year":"2013","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.7150\/ijbs.120980","article-title":"Metabolic Syndrome-Associated Erectile Dysfunction: Multiple Vascular Endothelial Dysfunction Mechanisms and Potential Therapeutic Targets","volume":"21","author":"Wang","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"15579883241282385","DOI":"10.1177\/15579883241282385","article-title":"Association of the VEGF 2578C>A Polymorphism With Metabolic Syndrome and Erectile Dysfunction","volume":"18","author":"Liu","year":"2024","journal-title":"Am. J. Mens. Health"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"101332","DOI":"10.1016\/j.ajpc.2025.101332","article-title":"Erectile dysfunction and cardiovascular-kidney-metabolic syndrome: Insights from the all of us research program","volume":"24","author":"Blazoski","year":"2025","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"100937","DOI":"10.1016\/j.molmet.2020.01.001","article-title":"Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies","volume":"35","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/humupd\/dmq001","article-title":"Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis","volume":"16","author":"Moran","year":"2010","journal-title":"Hum. Reprod. Update"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/obr.12762","article-title":"Metabolic syndrome in polycystic ovary syndrome: A systematic review, meta-analysis and meta-regression","volume":"20","author":"Lim","year":"2019","journal-title":"Obes. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/cen.12068","article-title":"Diabetes and cardiovascular events in women with polycystic ovary syndrome: A 20-year retrospective cohort study","volume":"78","author":"Mani","year":"2013","journal-title":"Clin. Endocrinol."},{"key":"ref_86","first-page":"e37266","article-title":"Risk of Gynecological Cancers in Women With Polycystic Ovary Syndrome and the Pathophysiology of Association","volume":"15","author":"Shetty","year":"2023","journal-title":"Cureus"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e70086","DOI":"10.1111\/obr.70086","article-title":"Effect of Metabolic Factors on the Risk of Colorectal Precancerous Polyps Among Individuals at Above-Average Risk for Colorectal Cancer: A Systematic Review and Meta-Analysis","volume":"27","author":"Molla","year":"2026","journal-title":"Obes. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jare.2024.02.007","article-title":"A narrative review about cognitive impairment in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Another matter to face through a holistic approach","volume":"68","author":"Meroni","year":"2025","journal-title":"J. Adv. Res."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Shea, S., Lionis, C., Kite, C., Lagojda, L., Uthman, O.A., Dallaway, A., Atkinson, L., Chaggar, S.S., Randeva, H.S., and Kyrou, I. (2024). Non-alcoholic fatty liver disease and coexisting depression, anxiety and\/or stress in adults: A systematic review and meta-analysis. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1357664"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Lizarzaburu-Robles, J.C., Herman, W.H., Garro-Mendiola, A., Gald\u00f3n Sanz-Pastor, A., and Lorenzo, O. (2024). Prediabetes and Cardiometabolic Risk: The Need for Improved Diagnostic Strategies and Treatment to Prevent Diabetes and Cardiovascular Disease. Biomedicines, 12.","DOI":"10.3390\/biomedicines12020363"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1210\/jc.2018-00468","article-title":"One-Hour Postload Hyperglycemia: Implications for Prediction and Prevention of Type 2 Diabetes","volume":"103","author":"Fiorentino","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41591-020-1116-9","article-title":"Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes","volume":"27","author":"Wagner","year":"2021","journal-title":"Nat. Med."},{"key":"ref_93","first-page":"e45835","article-title":"Cardiovascular Complications of Diabetes: From Microvascular to Macrovascular Pathways","volume":"15","author":"Zakir","year":"2023","journal-title":"Cureus"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.2337\/dc08-0423","article-title":"Metabolic syndrome and incident diabetes: Current state of the evidence","volume":"31","author":"Ford","year":"2008","journal-title":"Diabetes Care"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Test, T., Press, Y., Freud, T., Kannai, R., and Satran, R. (2025). Metabolic Syndrome and Risk of New-Onset Type 2 Diabetes Mellitus: An Eight-Year Follow-Up Study in Southern Israel. Diabetology, 6.","DOI":"10.3390\/diabetology6120150"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Scaglione, S., Di Chiara, T., Daidone, M., and Tuttolomondo, A. (2025). Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk. Nutrients, 17.","DOI":"10.3390\/nu17020358"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Monserrat-Mesquida, M., Bouzas, C., Garc\u00eda, S., Mateos, D., Casares, M., Ugarriza, L., G\u00f3mez, C., Sureda, A., and Tur, J.A. (2025). Two-Year Mediterranean Diet Intervention Improves Hepatic Health in MASLD Patients. Foods, 14.","DOI":"10.3390\/foods14101736"},{"key":"ref_98","first-page":"e0856","article-title":"Mediterranean and low-fat diets are equally effective in MASLD resolution at 12 weeks regardless of PNPLA3 genotype: A randomized controlled trial","volume":"9","author":"Innocenti","year":"2025","journal-title":"Hepatol. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Prieto-Gonz\u00e1lez, P., Yagin, F.H., Alghannam, A.F., and Canli, U. (2025). Effects of a Mediterranean diet and structured exercise intervention on selected anthropometric, cardiovascular, and metabolic variables in physically inactive adults: A randomized controlled trial. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1695412"},{"key":"ref_100","unstructured":"(2026, July 14). ClinicalTrials.gov. Structured Physical Activity Intervention in Patients with MASLD Receiving a Mediterranean Diet (EHMet-DIA). ClinicalTrials.gov Identifier: NCT07478588, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07478588."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1161\/CIR.0000000000001189","article-title":"Resistance Exercise Training in Individuals With and Without Cardiovascular Disease: 2023 Update: A Scientific Statement From the American Heart Association","volume":"149","author":"Paluch","year":"2024","journal-title":"Circulation"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"112077","DOI":"10.1016\/j.diabres.2025.112077","article-title":"Resistance exercise training and its impact on metabolic syndrome in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"222","author":"Han","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/1753-0407.12614","article-title":"Resistance training reduces metabolic syndrome and inflammatory markers in older women: A randomized controlled trial","volume":"10","author":"Tomeleri","year":"2018","journal-title":"J. Diabetes"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Nilsson, M.I., Xhuti, D., de Maat, N.M., Hettinga, B.P., and Tarnopolsky, M.A. (2024). Obesity and Metabolic Disease Impair the Anabolic Response to Protein Supplementation and Resistance Exercise: A Retrospective Analysis of a Randomized Clinical Trial with Implications for Aging, Sarcopenic Obesity, and Weight Management. Nutrients, 16.","DOI":"10.3390\/nu16244407"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Tiwari, A., Sharma, A., Kumar, H., Gupta, V., Deshpande, V., Mupparaju, J.S., Mishra, T., Bharadwaj, H.R., Dahiya, D.S., and Jain, V. (2025). Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier. Biomedicines, 13.","DOI":"10.3390\/biomedicines13092079"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for Obesity Treatment and Diabetes Prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/17512433.2025.2573785","article-title":"Semaglutide for the treatment of MASH: Reaching into the ESSENCE of cardio-metabolic health?","volume":"18","author":"Mademlis","year":"2025","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12933-025-02700-0","article-title":"CVOT summit report 2024: New cardiovascular, kidney, and metabolic outcomes","volume":"24","author":"Schnell","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Suki, M., Imam, A., Amer, J., Milgrom, Y., Massarwa, M., Hazou, W., Tiram, Y., Perzon, O., Sharif, Y., and Sackran, J. (2025). SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic. Pharmaceuticals, 18.","DOI":"10.3390\/ph18081118"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"7459","DOI":"10.1038\/s41467-025-62891-8","article-title":"A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD","volume":"16","author":"Wu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"104366","DOI":"10.1016\/j.numecd.2025.104366","article-title":"Effects of dapagliflozin on mortality across the spectrum of cardiovascular-kidney-metabolic syndrome: A meta-analysis","volume":"36","author":"Paolillo","year":"2026","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"107794","DOI":"10.1016\/j.pharmthera.2020.107794","article-title":"The evolving obesity challenge: Targeting the vagus nerve and the inflammatory reflex in the response","volume":"222","author":"Pavlov","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"a034215","DOI":"10.1101\/cshperspect.a034215","article-title":"Noninvasive Neuromodulation of Peripheral Nerve Pathways Using Ultrasound and Its Current Therapeutic Implications","volume":"10","author":"Puleo","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/intimm\/dxab073","article-title":"Control of inflammation using non-invasive neuromodulation: Past, present and promise","volume":"34","author":"Tynan","year":"2022","journal-title":"Int. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Ji, Y., Lee, H., Kaura, S., Yip, J., Sun, H., Guan, L., Han, W., and Ding, Y. (2021). Effect of Bariatric Surgery on Metabolic Diseases and Underlying Mechanisms. Biomolecules, 11.","DOI":"10.3390\/biom11111582"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e046837","DOI":"10.1161\/JAHA.125.046837","article-title":"Finerenone Prescriptions in the United States (2021\u20132024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular-Kidney-Metabolic Space","volume":"15","author":"Jelwan","year":"2026","journal-title":"J. Am. Heart Assoc."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1742\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:55:38Z","timestamp":1789034138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":122,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medicina62091742"],"URL":"https:\/\/doi.org\/10.3390\/medicina62091742","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}